Gold nanoparticles as novel agents for cancer therapy
S Jain, DG Hirst, JM O'Sullivan - The British journal of radiology, 2012 - birpublications.org
Gold nanoparticles are emerging as promising agents for cancer therapy and are being
investigated as drug carriers, photothermal agents, contrast agents and radiosensitisers. This …
investigated as drug carriers, photothermal agents, contrast agents and radiosensitisers. This …
Radiation-induced bystander signalling in cancer therapy
KM Prise, JM O'sullivan - Nature Reviews Cancer, 2009 - nature.com
Our understanding of how radiation kills normal and tumour cells has been based on an
intimate knowledge of the direct induction of DNA damage and its cellular consequences. What …
intimate knowledge of the direct induction of DNA damage and its cellular consequences. What …
[HTML][HTML] A review of feature selection methods for machine learning-based disease risk prediction
Machine learning has shown utility in detecting patterns within large, unstructured, and complex
datasets. One of the promising applications of machine learning is in precision medicine…
datasets. One of the promising applications of machine learning is in precision medicine…
[HTML][HTML] Alpha emitter radium-223 and survival in metastatic prostate cancer
…, D Heinrich, SI Helle, JM O'Sullivan… - … England Journal of …, 2013 - Mass Medical Soc
Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone
metastases with alpha particles. We assessed the efficacy and safety of radium-223 as …
metastases with alpha particles. We assessed the efficacy and safety of radium-223 as …
[HTML][HTML] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
…, R Laing, F McKinna, DB McLaren, JM O'Sullivan… - The Lancet, 2016 - thelancet.com
Background Long-term hormone therapy has been the standard of care for advanced prostate
cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, …
cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, …
[HTML][HTML] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
…, S Jonnada, S Khaksar, JF Lester, JM O'sullivan… - The Lancet, 2018 - thelancet.com
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
[HTML][HTML] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
…, J Logue, Z Malik, J Money-Kyrle, JM O'Sullivan… - The Lancet …, 2016 - thelancet.com
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
COVID19 coagulopathy in Caucasian patients
…, K Ryan, N O'Connell, JM O'Sullivan… - British journal of …, 2020 - Wiley Online Library
Although the pathophysiology underlying severe COVID19 remains poorly understood,
accumulating data suggest that a lung‐centric coagulopathy may play an important role. …
accumulating data suggest that a lung‐centric coagulopathy may play an important role. …
Persistent endotheliopathy in the pathogenesis of long COVID syndrome
…, M Byrne, C Bergin, JM O'Sullivan… - … of thrombosis and …, 2021 - Wiley Online Library
Background Persistent symptoms including breathlessness, fatigue, and decreased exercise
tolerance have been reported in patients after acute SARS‐CoV‐2 infection. The biological …
tolerance have been reported in patients after acute SARS‐CoV‐2 infection. The biological …
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3 …
…, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan… - The Lancet …, 2014 - thelancet.com
Background Bone metastases frequently cause skeletal events in patients with metastatic
castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets …
castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets …